- Eiger BioPharmaceuticals (NASDAQ:EIGR) +11.6% after-hours on news that the U.S. Food and Drug Administration granted approval of its Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of some processing-deficient progeroid laminopathies.
- Progeria and progeroid laminopathies are separate ultra-rare, genetic, premature aging diseases that accelerate mortality in young patients.
- Earlier this week, Eiger BioPharma reported positive end-of-study reports for its peginterferon lambda-lonafarnib combination in treatment of hepatitis delta virus.
- https://seekingalpha.com/news/3638513-fda-oks-eiger-biopharmas-hutchinson-gilford-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.